C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 5.24 USD 1.55%
Market Cap: 87.6m USD
Have any thoughts about
Coya Therapeutics Inc?
Write Note

Coya Therapeutics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Coya Therapeutics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
C
Coya Therapeutics Inc
NASDAQ:COYA
Income from Continuing Operations
-$8m
CAGR 3-Years
-122%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Coya Therapeutics Inc
Glance View

Market Cap
79.8m USD
Industry
Biotechnology

Coya Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation. The company is headquartered in Houston, Texas. The company went IPO on 2022-12-29. The firm is focused on developing new therapies to enhance the function of regulatory T cells (Tregs). The company is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. The company has a diversified product candidate pipeline that includes both ex vivo (outside the body) and in vivo (inside the body) therapeutic approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Its 300 Series product candidates include COYA 301 and COYA 302, its 200 Series product candidates include COYA 201 and COYA 206, and its 100 Series product candidate is COYA 101. Its COYA 301 is a biologic for subcutaneous administration. Its COYA 302 is a combination of two molecules for subcutaneous and/or intravenous administration. Its COYA 201 product candidate utilizes its Treg-derived exosome therapeutic modality. Its COYA 101 is its autologous regulatory T-cell product candidate.

COYA Intrinsic Value
1.33 USD
Overvaluation 75%
Intrinsic Value
Price
C

See Also

What is Coya Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-8m USD

Based on the financial report for Dec 31, 2023, Coya Therapeutics Inc's Income from Continuing Operations amounts to -8m USD.

What is Coya Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-122%

Over the last year, the Income from Continuing Operations growth was 35%. The average annual Income from Continuing Operations growth rates for Coya Therapeutics Inc have been -122% over the past three years .

Back to Top